ARCHIVES

Early ADT Doesn’t Offer Survival Advantage—ASCO

This article is from The Cancer Letter archive.

Vol. 30 No. 4 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI CTEP Last Month

January 28, 2011

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

October 31, 2014

Cancer Letter Founder Receives ACCC Award, Stresses Importance Of Bypass Budget

March 20, 1992

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Jerome Yates Named VP For Research At ACS

February 8, 2002

SWOG Plans Increase in Payments to Centers for Trial Accrual.

May 25, 2007